Liraglutide: a once-daily GLP-1 analogue for the treatment of Type 2 diabetes mellitus
- 24 January 2007
- journal article
- review article
- Published by Informa Healthcare in Expert Opinion on Investigational Drugs
- Vol. 16 (2) , 231-237
- https://doi.org/10.1517/13543784.16.2.231
Abstract
(2007). Liraglutide: a once-daily GLP-1 analogue for the treatment of Type 2 diabetes mellitus. Expert Opinion on Investigational Drugs: Vol. 16, No. 2, pp. 231-237. doi: 10.1517/13543784.16.2.231Keywords
This publication has 54 references indexed in Scilit:
- The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetesPublished by Elsevier ,2006
- Effects of liraglutide (NN2211), a long‐acting GLP‐1 analogue, on glycaemic control and bodyweight in subjects with Type 2 diabetesDiabetic Medicine, 2005
- New sources of pancreatic β-cellsNature Biotechnology, 2005
- Standards of Medical Care in DiabetesDiabetes Care, 2005
- GLP‐1 receptor agonists are growth and differentiation factors for pancreatic islet beta cellsDiabetes/Metabolism Research and Reviews, 2003
- Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)The Lancet, 1998
- Glucagon-Like Peptide 1 and its Potential in the Treatment of Non-Insulin-Dependent Diabetes MellitusHormone and Metabolic Research, 1997
- Rapid Gastric Emptying of a Solid Pancake Meal in Type II Diabetic PatientsDiabetes Care, 1996
- Ileal release of glucagon-like peptide-1 (GLP-1)Digestive Diseases and Sciences, 1995
- Clinical aspects of islet B‐cell function in non‐insulin‐dependent diabetes mellitusDiabetes/Metabolism Research and Reviews, 1986